September 23, 2020 10:53 AM EDTUpdated 11:33 AM
Coronavirus

J&J re­leas­es PhI­II safe­ty blue­print for Covid-19 vac­cine tri­al. How does it stack up to Mod­er­na, Pfiz­er and As­traZeneca?

Max Gelman

Senior Editor

Along with the ini­ti­a­tion of its Phase III Covid-19 vac­cine study an­nounced Wednes­day morn­ing, John­son & John­son al­so re­leased its tri­al pro­to­col, giv­ing an in­side …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

'We play to win': As­traZeneca de­tails first re­sults for oral GLP-1 and broad­er obe­si­ty am­bi­tions

Is there room for MASH drugs in a GLP-1 world?

FDA cites Mark Cuban's drug com­pound­ing cen­ter in Dal­las with steril­i­ty, qual­i­ty con­cerns

Viking's oral weight loss drug ap­pears to have strong ef­fect in Phase 1 tri­al

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times